Emergent Biosolutions (EBS)

• Market cap: $277M
• 1 day: 2.61%
• 5 days: 10.13%
• 1 month: -10.82%
• 3 months: -56.17%
• 6 months: -43.60%
• Year to date: -50.24%
• 1 year: 134.40%
• 5 years: -93.03%
• 10 years: -83.31%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 1,600

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

116% more call options, than puts

Call options by funds: $4.86M | Put options by funds: $2.25M

76% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 21

28% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 36

26% more capital invested

Capital invested by funds: $265M [Q3] → $332M (+$67.5M) [Q4]

11% more funds holding

Funds holding: 140 [Q3] → 156 (+16) [Q4]

5.46% more ownership

Funds ownership: 58.66% [Q3] → 64.12% (+5.46%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 194% upside
• Avg. target: $15 194% upside
• High target: $15 194% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 95 / 331 met price target

194% upside $15

Buy Reiterated

1 Apr 2025